Newbury Pharmaceuticals AB is a Sweden-based pharmaceutical company for specialty prescription drugs. The Companyâ€™s existing portfolio is focused on the Scandinavian market and consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology.

Employees

Sector

Drug Retailers

Calendar

10-27 Earnings release - Annual 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-08	SEK 2.140	-2.73%	450
26-10-07	SEK 2.200	+3.77%	32,624
26-10-06	SEK 2.120	-4.50%	10,680
26-10-05	SEK 2.220	0.00%	50
26-10-02	SEK 2.220	-0.45%	88,268

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Newbury Pharmaceuticals AB

Company calendar

Delayed Nasdaq Stockholm 04:41:20 2026-10-08 EDT			5-day change	1st Jan Change
2.140 ^SEK	-2.73%		-7.36%	+86.09%

09-28	Newbury Pharmaceuticals AB, through its subsidiary Newbury Pharmaceuticals S.A Secure Exclusive Rights to 40-Product Hospital Portfolio in Iraq	CI
07-13	Newbury Pharmaceuticals Secures Generic Approval for Tofacitinib Newbury	CI

Market Cap	76.3M 7.62M 6.81M 6.35M 5.77M 10.86M 737M 10.94M 29.81M 375M 28.59M 27.98M 1.2B	P/E 2024	-4.59x	P/E 2025	-2.81x
Enterprise Value	61.74M 6.16M 5.51M 5.14M 4.67M 8.79M 596M 8.85M 24.12M 303M 23.14M 22.64M 975M	EV / Sales 2024	1.76x	EV / Sales 2025	2.03x
Free-Float	25.89%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	NEWBRY	Delayed
Deutsche Boerse AG	P52	Delayed

09-28	Newbury Pharmaceuticals AB, through its subsidiary Newbury Pharmaceuticals S.A Secure Exclusive Rights to 40-Product Hospital Portfolio in Iraq	CI
07-13	Newbury Pharmaceuticals Secures Generic Approval for Tofacitinib Newbury	CI
07-10	Newbury Pharmaceuticals Secures Generic Approval for Dalbavancin Newbury	CI
07-08	Newbury Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI
06-16	Navamedic CEO Steps Down; Successor Named	MT
04-17	Newbury Pharmaceuticals Wins Danish Approval for Generic Breast Cancer Drug	MT
04-17	Newbury Pharmaceuticals Secures Generic Approval for Palbociclib Newbury	CI
04-15	Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2026	CI
04-15	Newbury pharmaceuticals Q2 EBITDA loss deepens to SEK 4.1 million	RE
04-15	Newbury Pharmaceuticals AB Provides Earnings Guidance for the Second Half of the Financial Year 2026	CI
03-27	Newbury Pharmaceuticals Seeks Shareholder Approval to Expand Loan Facility to SEK30 Million	MT
03-18	Newbury pharmaceuticals enters into new partnership	RE
03-18	Newbury Pharmaceuticals Signs Contract to Register and Launch Prucalopride Tablets in Sweden	CI

Newbury Pharmaceuticals AB Stock

Stocks

NEWBRY

SE0015244884

Drug Retailers

Valuation: Newbury Pharmaceuticals AB

Chart: Newbury Pharmaceuticals AB

Latest news: Newbury Pharmaceuticals AB

Analysts' recommendations: Newbury Pharmaceuticals AB

Press Releases: Newbury Pharmaceuticals AB

Quotes and Performance

Price Extremes

Managers and Directors: Newbury Pharmaceuticals AB

Retail - Drugs without Grocery

Financials

Company Profile

Quotes

Net sales - Rate of surprise

23-01-12	Redeye adjusts downwards its motivated value for Newbury Pharmaceuticals	FW
23-01-12	Redeye lowers motivated value for Newbury Pharmaceuticals to SEK 8.5 (9)	FW

09-28	Newbury Pharmaceuticals secures exclusive rights to a 40-product hospital portfolio in Iraq	AQ
08-17	Newbury Pharmaceuticals : accelerates its neuroscience ambitions with a new partnership for Guanfacine tablets	PU
07-13	Newbury Pharmaceuticals Secures Generic Approval for Tofacitinib Newbury	AQ
07-10	Newbury Pharmaceuticals Secures Generic Approval for Dalbavancin Newbury	AQ
07-08	Newbury Pharmaceuticals interim report September 2025 – May 2026	AQ

1 day	-2.73%
1 week	-7.36%
Current month	-7.36%
1 month	-2.28%
3 months	-8.55%
6 months	+94.55%
Current year	+86.09%

1 week	2.1	2.31
1 month	2.1	2.51
Current year	0.76	7.88
1 year	0.76	7.88
3 years	0.76	7.88
5 years	0.76	13.7
10 years	0.76	13.7

Manager	Title	Age	Since
Karl Karlsson CEO	Chief Executive Officer	52	2025-11-10
Christoffer Tell DFI	Director of Finance/CFO	39	2020-12-31
Andrea Karnitschky PRN	Corporate Officer/Principal	-	2022-07-31

Director	Title	Age	Since
Hakan Andreas Hedskog BRD	Director/Board Member	52	2019-12-31
Anil Okay BRD	Director/Board Member	40	2020-12-31
Johan Strömqvist BRD	Director/Board Member	50	2019-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEWBURY PHARMACEUTICALS AB	-2.73%	-7.36%	-14.40%	-32.49%	6.68M
JD HEALTH INTERNATIONAL INC.	+0.06%	-1.78%	-47.03%	-7.19%	14.36B
RAIA DROGASIL S.A.	-0.85%	+14.81%	+16.41%	-22.45%	7.37B
TSURUHA HOLDINGS INC.	+2.25%	+0.76%	-9.55%	-1.89%	5.98B
MATSUKIYOCOCOKARA & CO.	+0.88%	+1.01%	-16.88%	-8.60%	6.07B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-0.35%	-1.92%	-57.62%	-40.47%	5.81B
YIFENG PHARMACY CHAIN CO., LTD.	+1.30%	+1.30%	-5.44%	-20.24%	4.22B
COSMOS PHARMACEUTICAL CORPORATION	+0.51%	+3.35%	-23.60%	-20.01%	3.17B
NAHDI MEDICAL COMPANY	-0.55%	0.00%	-24.54%	-35.92%	3.17B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	+2.08%	+2.08%	+10.37%	-27.63%	3.09B
Average	+0.26%	+1.79%	-17.23%	-21.69%	5.32B
Weighted average by Cap.	+0.43%	+2.28%	-22.39%	-17.20%

	2024	2025
Net sales	36.83M 3.68M 3.28M 3.06M 2.78M 5.24M 356M 5.28M 14.39M 181M 13.8M 13.5M 581M	31.57M 3.15M 2.82M 2.63M 2.39M 4.49M 305M 4.53M 12.33M 155M 11.83M 11.58M 498M
Net income	-15.4M -1.54M -1.37M -1.28M -1.16M -2.19M -149M -2.21M -6.02M -75.66M -5.77M -5.65M -243M	-23.88M -2.38M -2.13M -1.99M -1.81M -3.4M -231M -3.43M -9.33M -117M -8.95M -8.76M -377M
Net Debt	-15.3M -1.53M -1.36M -1.27M -1.16M -2.18M -148M -2.19M -5.98M -75.16M -5.74M -5.61M -242M	-14.56M -1.45M -1.3M -1.21M -1.1M -2.07M -141M -2.09M -5.69M -71.52M -5.46M -5.34M -230M